A prospective study is being undertaken in Western Kenya to evaluate the effectiveness and tolerability of WHo-MDT, while at the same time comparing it to a modified multidrug regimen, which is rifampicin 1500mg at the onset supervised, and repeated after 3 months and dapsone 100mg daily for 6 months.
Preliminary analysis done on 127 cases admitted into the study are presented.
The inactivity index observed between 0-12 weeks was 20% for WHO-MDT and 47% for modified-MDT (p<0.01).
The inactivity index observed between 0-24 weeks was 63.3% for WHO-MDT and 82.3% for modified-MDT (p<0.05).
The inactivity index observed between 0-32 weeks was 83% for WHO-MDT, and 88% for modified-MDT.
Mots-clés Pascal : Mycobactériose, Bactériose, Infection, Afrique, Lèpre, Kenya, Plan traitement, OMS, Antibiotique, Peau pathologie, Homme
Mots-clés Pascal anglais : Mycobacterial infection, Bacteriosis, Infection, Africa, Leprosy, Kenya, Treatment planning, WHO, Antibiotic, Skin disease, Human
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 91-0210091
Code Inist : 002B02S02. Création : 199406.